Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Goldman Sachs raised the firm’s price target on JPMorgan (JPM) to $295 from $273 and keeps a Buy rating on the shares. The firm cites the ...

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

JPMorgan, Wells Fargo, Goldman Sachs and Citi kicked off earnings season on Wednesday with their December-quarter results.

Fresh off a record year for profit and revenue, JPMorgan is facing questions over what CFO Jeremy Barnum admitted was excess ...

The bank said profit rose 50% to $14 billion in the fourth quarter as noninterest expenses fell 7% from a year earlier.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...